474 related articles for article (PubMed ID: 30407206)
1. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
Wu AY; Sur S; Grant JA; Tripple JW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
3. Biological therapies for eosinophilic asthma.
Patel SS; Casale TB; Cardet JC
Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
[TBL] [Abstract][Full Text] [Related]
4. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
5. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
7. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
Parulekar AD; Kao CC; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab utility in difficult-to-treat asthma.
M Walsh G
Immunotherapy; 2019 Mar; 11(4):261-264. PubMed ID: 30678554
[No Abstract] [Full Text] [Related]
9. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for the treatment of asthma.
Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
[TBL] [Abstract][Full Text] [Related]
12. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
13. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
Maeda S; Yanagihara Y
Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
[TBL] [Abstract][Full Text] [Related]
14. Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks.
Beckert H; Meyer-Martin H; Buhl R; Taube C; Reuter S
J Immunol; 2020 Feb; 204(3):550-558. PubMed ID: 31862712
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
18. Biologic and New Therapies in Asthma.
Tabatabaian F; Ledford DK; Casale TB
Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
[TBL] [Abstract][Full Text] [Related]
19. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
20. Commonality of the IL-4/IL-13 pathway in atopic diseases.
Gandhi NA; Pirozzi G; Graham NMH
Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]